Estrogen receptor (ER) and human epidermal growth factor receptor 2 (HER2) are often examined, but their expressions are detected in 12–25% and 20% of gastric cancers [4–6], and in 30–56% and 4–14% of colon cancers [7–10], respectively. Here, ESR1 is linked to malignant colon neoplasm.